Surging GLP-1 revenues threaten the terminal value of ultra-processed food and bariatric devices

The GLP-1 Duopoly Forces a Reallocation of Global Healthcare Spending

A concentrated duopoly dominates the pharmaceutical industry and alters global healthcare spending. Novo Nordisk and Eli Lilly control the GLP-1 receptor agonist market, generating revenue at a scale that has shifted equity values across the healthcare sector. Unprecedented clinical efficacy in weight loss collides with the structural constraints of healthcare budgets. With Novo Nordisk capturing a 70.4% volume share of a branded obesity market that expanded 119% in a single year, and Eli Lilly seeing quarterly revenues soar 45% to $13.53 billion, the adoption curve is steeper than any blockbuster drug in history. The financial burden of chronic disease is shifting, requiring insurers, employers, and governments to decide whether to absorb massive upfront drug costs in exchange for theoretical long-term medical savings.